The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus
Open accessAbstract
BACKGROUND: It is unknown whether canagliflozin, a selective sodium glucose co-transporter 2 inhibitor, reduces epicardial adipose tissue (EAT) thickness, which is associated with insulin resistance and is a risk factor for coronary artery disease. METHODS AND RESULTS: We administered 100 mg of canagliflozin for 6 months to 13 patients with type 2 diabetes mellitus. We evaluated glycemic control, visceral adipose tissue (VAT) area and subcutaneous adipose tissue (SAT) area, and skeletal muscle mass by using impedance methods, and EAT thickness by using echocardiography. Canagliflozin treatment for 6 months decreased hemoglobin A1c level from 7.1 ± 0.5% to 6.7 ± 0.6% (P < 0.05) and decreased EAT thickness from 9.3 ± 2.5 to 7.3 ± 2.0 mm (P < 0.001), along with a trend of decreasing VAT and SAT area. No association was found between any of these changes. CONCLUSION: Canagliflozin reduced EAT thickness in patients with type 2 diabetes mellitus independent of its effect on lowering blood glucose, suggesting that canagliflozin may have an effect in preventing cardiovascular events in these patients (UMIN000021327).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
Merovci, A., Solis-Herrera, C., Daniele, G., Eldor, R., Fiorentino, T. V., Tripathy, D., Xiong, J., Perez, Z., Norton, L., Abdul-Ghani, M. A., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci70704 · Cited by 795
Epicardial adipose tissue and insulin resistance in obese subjects
Iacobellis, G., & Leonetti, F. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1087 · Cited by 355
Substantial changes in epicardial fat thickness after weight loss in severely obese subjects
Iacobellis, G., Singh, N., Wharton, S., & Sharma, A. M. (2008) · Obesity · doi:10.1038/oby.2008.251 · Cited by 238 · cited 1×
“It has been reported that weight loss [20], bariatric surgery [8], exercise [21], or atorvastatin therapy [22, 23] lead to a regression of EAT.”
BackgroundRabkin, S. W., & Campbell, H. (2015) · Obesity Reviews · doi:10.1111/obr.12270 · Cited by 114
Cited by
Epicardial adipose tissue in contemporary cardiology
Iacobellis, G. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00679-9 · Cited by 797
SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control
Cowie, M. R., & Fisher, M. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0406-8 · Cited by 784
Mechanistic Insights of Empagliflozin in Nondiabetic Patients With HFrEF
Requena-Ibáñez, J. A., Santos-Gallego, C. G., Rodriguez-Cordero, A., Vargas-Delgado, A. P., Mancini, D., Sartori, S., Atallah-Lajam, F., Giannarelli, C., Macaluso, F., Lala, A., et al. (2021) · JACC: Heart Failure · doi:10.1016/j.jchf.2021.04.014 · Cited by 264
Obesity-Related Heart Failure With a Preserved Ejection Fraction
Packer, M., & Kitzman, D. W. (2018) · JACC: Heart Failure · doi:10.1016/j.jchf.2018.01.009 · Cited by 172
Christensen, R. H., Wedell-Neergaard, A.-S., Lehrskov, L. L., Legaard, G. E., Dorph, E., Larsen, M. K., Launbo, N., Fagerlind, S. R., Seide, S. K., Nymand, S., et al. (2019) · JAMA Cardiology · doi:10.1001/jamacardio.2019.2074 · Cited by 111
Metadata
- Authors
- Yagi, S., Hirata, Y., Ise, T., Kusunose, K., Yamada, H., Fukuda, D., Salim, H. M., Maimaituxun, G., Nishio, S., Takagawa, Y., Hama, S., Matsuura, T., Yamaguchi, K., Tobiume, T., Soeki, T., Wakatsuki, T., Aihara, K.-I., Akaike, M., Shimabukuro, M., & Sata, M.
- Venue
- Diabetology & Metabolic Syndrome
- Published
- 2017-10-04
- Volume
- 9
- Issue
- 1
- Pages
- 78-78
- ISSN
- 1758-5996 (ISSN-L)
- OpenAlex
- W2764144227
- Cited by
- 179
- References
- 5
- FWCI
- 8.70
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus. https://app.cochat.ai/papers/10.1186/s13098-017-0275-4
- The paper
- Yagi, S., Hirata, Y., Ise, T., Kusunose, K., Yamada, H., Fukuda, D., Salim, H. M., Maimaituxun, G., Nishio, S., Takagawa, Y., Hama, S., Matsuura, T., Yamaguchi, K., Tobiume, T., Soeki, T., Wakatsuki, T., Aihara, K.-I., Akaike, M., Shimabukuro, M., & Sata, M. (2017). Canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus. Diabetology & Metabolic Syndrome. https://doi.org/10.1186/s13098-017-0275-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.